Peptide Regulatory Status: FDA, EMA and the Gray Zone

"Are peptides legal?" sounds like a yes-or-no question. It is not. A compound can be approved for one indication, under clinical investigation, withdrawn, or simply never evaluated. These categories are not interchangeable. Most research peptides belong to the last one: they have never been submitted for regulatory review for human use in any jurisdiction.

This article describes how regulatory frameworks work. It is not legal advice and it does not settle any individual's situation, which depends on their country and their circumstances.

The five categories and what each one means

Confusing them is the source of almost every misunderstanding in this sector.

The two most frequent mix-ups:

"It's in phase 3" is not "almost approved." A meaningful share of molecules that reach phase 3 never obtain approval, and among those that do, many are approved for narrower indications than the ones studied.

"Never evaluated" is not "banned." It is an absence, not a decision. Nobody has said no; nobody has said yes. That gap is exactly what the research use only label describes.

United States: the FDA and the compounding question

In the United States there are two routes by which a peptide can legally reach a person, and they are worth telling apart.

The full approval route. The manufacturer submits a dossier with preclinical data and data from three clinical phases, and the FDA authorizes (or does not authorize) marketing for an indication. This is the path semaglutide and tesamorelin took.

The compounding route. Pharmacies licensed under sections 503A and 503B of federal law can prepare customized medications from bulk substances. Which substances they may use is regulated, and that is where peptides come in.

The FDA sorts substances nominated for use in compounding into categories. The one that matters here is Category 2: substances that, in the agency's assessment, raise significant safety risks and that, while the review is underway, cannot be used in compounding.

The arguments the FDA has made for placing peptides in that category turn on three axes: immunogenicity risk depending on the route of administration, difficulty in characterizing the active ingredient, and the complexity of the peptide-related impurity profile.

And here is the important warning in this section: that list changes. There have been additions and also removals, some because the nominating party withdrew the nomination, others after review by the relevant advisory committee. Any list published on a blog ages within months.

That is why this article does not publish a list of compounds by category. What helps is not memorizing a status with an expiration date, but knowing where to check it: the FDA itself keeps the current list in its human drug compounding section, and that is the only source that reflects today's state of play.

European Union: the EMA and the national agencies

The European system has two levels, and both matter.

The EMA evaluates and issues a scientific opinion; formal authorization is granted by the European Commission, and under the centralized procedure it is valid in every member state at once.

The national agencies (AEMPS in Spain, ANSM in France and their counterparts) keep authority over national authorizations, pharmacovigilance, inspection and, above all, over enforcement against the marketing of unauthorized products in their territory.

That second power is the one that tends to surprise people. A molecule without European authorization is not sitting in a neutral limbo: promoting and selling it for human use falls within the remit of the corresponding national agency. In general terms, the European framework is more restrictive than the American or the Colombian one when it comes to promoting unauthorized substances.

Colombia: the INVIMA framework

In Colombia, INVIMA is the health authority that grants the sanitary registration, without which a medicine cannot be marketed or promoted for therapeutic use in the country.

The points that frame the situation:

• A research peptide has no sanitary registration because nobody has applied for one. There is no dossier that INVIMA rejected; there is simply no dossier.
• Importing products subject to health surveillance is regulated, and the declared purpose determines which regime applies.
• Promoting a product without registration using therapeutic indications is what the framework restricts most clearly.

What this article cannot do is tell any individual what all of this means in their case. That depends on purpose, quantity, channel and individual circumstances, and it is a conversation with a lawyer who practices in the country. Any blog that answers that in absolute terms is claiming to know more than it can.

Why "legal for research" is not the same as "legal for human use"

This is the false equivalence holding up much of the market, and it deserves to be taken apart piece by piece.

A laboratory reagent can be manufactured, sold and bought legally for use in research. That legality is tied to the declared purpose. The moment the actual purpose is human administration, the product leaves the category it was sold under, and a different framework applies: the one for medicines, where that product has no authorization.

The practical consequence is that the label does not travel with the product as a safe-conduct. It describes the framework the product was sold under, not the one that applies to whatever is done with it afterward.

And in the other direction, an equally important clarification: this does not automatically make it a crime to possess a research compound. The concrete consequences vary enormously between jurisdictions and between scenarios. The defensible claim is more modest: the protection many people believe they get by buying something labeled RUO is narrower than they assume.

What any buyer should demand from a supplier

Whatever the jurisdiction, there is a verifiable minimum:

1. A certificate of analysis for the specific lot, not for the brand in general. How to read one.
2. An identifiable issuing laboratory, with an accession number you can look up on its own portal.
3. Labeling consistent with what the product is: no therapeutic indications, no promises of results.
4. Lot traceability: the code on the vial that arrives should match the one on the document.
5. No claims the supplier cannot support. A seller who says their product "treats" something is declaring therapeutic properties for a product without registration, and that says more about the seller than about the product.

The certificates on this site are published with those elements so they can be checked.

What this article does not settle

The framework changes. FDA lists are revised, European agencies issue decisions and Colombian rules are updated. An article with a review date of August 2026 describes August 2026.

There is no global answer. "Are peptides legal?" has no single answer, because the question depends on the country, the compound, the purpose and the channel.

It does not replace legal advice. Describing categories is not the same as applying them to a case. That takes a professional who practices in the relevant jurisdiction.

And a methodological note on this text: we have deliberately avoided publishing lists of compounds by regulatory category. They would be the most sought-after content in the article and also the fastest to mislead, because they would be out of date before most readers reached them.

This content is strictly educational and does not constitute medical advice, diagnosis or a therapeutic recommendation. The compounds mentioned are research products (Research Use Only) and are not approved by INVIMA, FDA, EMA or ANSM for therapeutic use in humans. Any health-related decision should be made with a licensed medical professional.